| 阿帕替尼联合替吉奥用于初始治疗失败后晚期肝癌的疗效及安全性分析 |
| |
| 引用本文： | 郑中显,潘明. 阿帕替尼联合替吉奥用于初始治疗失败后晚期肝癌的疗效及安全性分析[J]. 蚌埠医学院学报, 2020, 45(7): 917-920. DOI: 10.13898/j.cnki.issn.1000-2020.07.020 |
| |
| 作者姓名： | 郑中显 潘明 |
| |
| 作者单位： | 安徽省池州市人民医院 腹部肿瘤病区, 247000 |
| |
| 摘 要： | 目的 评价阿帕替尼联合替吉奥用于初始治疗失败后晚期肝癌的疗效及安全性。 方法 选取87例经初始治疗失败后的晚期肝癌病人，其中46例接受阿帕替尼联合替吉奥治疗（观察组），41例接受替吉奥单药治疗（对照组），分别评估2组病人的总体疗效、生存情况、生活质量和不良反应。 结果 观察组客观缓解率和疾病控制率均明显高于对照组（P < 0.05）。观察组中位生存时间明显高于对照组（P < 0.05）。观察组病人生活质量好转率较对照组明显提高（P < 0.05）。阿帕替尼联合替吉奥的常见不良反应为蛋白尿、一过性转氨酶升高、白细胞降低、高血压、腹泻和食管炎，Ⅲ度或以上不良反应率与替吉奥单药差异无统计学意义（P>0.05）。 结论 阿帕替尼联合替吉奥用于初始治疗失败的晚期肝癌病人的近期疗效可观，并能延长病人的生存，有效改善了病人病程中的生活质量，且不良作用可耐受，值得进一步研究应用。
|
| 关 键 词： | 肝肿瘤 阿帕替尼 替吉奥 |
| 收稿时间： | 2020-01-28 |
Efficacy and safety of apatinib combined with tegafur in the treatment of liver cancer after the failure of initial treatment |
| |
| Affiliation: | Department of Abdominal Ward, Chizhou People's Hospital, Chizhou Anhui 247000, China |
| |
| Abstract: | Objective To evaluate the efficacy and safety of apatinib combined with tegafur in the treatment of liver cancer after the failure of initial treatment. Methods A total of 87 patients with advanced hepatocellular carcinoma after the failure of initial treatment were selected, 46 cases were treated with apatinib combined with tegafur (observation group), and 41 cases were treated with tegafur alone (control group).The clinical efficacy, survival, quality of life and adverse reactions were compared between two groups. Results The objective response rate and disease control rate in observation group were significantly higher than those in control group (P < 0.05).The median survival time in observation group were significantly higher than that in control group (P < 0.05).The improvement rate of life quality in observation group significantly increased compared with that in control group (P < 0.05).The proteinuria, transient transaminase lifts, white blood cells reducing, high blood pressure, diarrhea and esophagitis were the common adverse reactions of apatinib combined with tegafur, and the difference of Ⅲ degrees or more adverse reaction rate between two groups was not statistically significant (P>0.05). Conclusion The apatinib combined with tegafur in the treatment of liver cancer after the failure of initial treatment can improve the short-term efficacy, prolong the survival time and improve the quality of life, the adverse effects is tolerable, and it is worthy of further research and application. |
| |
| Keywords: | |
|
| 点击此处可从《蚌埠医学院学报》浏览原始摘要信息 |
|
点击此处可从《蚌埠医学院学报》下载免费的PDF全文 |
|
